DUBLIN--(BUSINESS WIRE)--The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
This Postmenopausal osteoporosis - Pipeline Insight, 2021 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal osteoporosis.
Postmenopausal osteoporosis Emerging Drugs Chapters
This segment of the Postmenopausal osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postmenopausal osteoporosis Emerging Drugs
TVB-009: Teva Pharmaceutical
TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in phase 3 of clinical trials.
Blosozumab: Eli Lilly and Company
Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis. It is a SOST protein inhibitor and is currently in phase 2 of clinical trials.
Postmenopausal osteoporosis: Therapeutic Assessment
Major Players in Postmenopausal osteoporosis
There are approx. 20+ key companies which are developing the therapies for Postmenopausal osteoporosis. The companies which have their Postmenopausal osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Postmenopausal osteoporosis drugs?
- How many Postmenopausal osteoporosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postmenopausal osteoporosis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postmenopausal osteoporosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Postmenopausal osteoporosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Teva Pharmaceutical
- Eli Lilly and Company
- Shanghai Biomabs Pharmaceutical
- Samsung Bioepis
- Qilu Pharmaceutical
- Shenzhen Salubris Pharmaceuticals
- Jiangsu HengRui Medicine Co., Ltd.
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Huons Co., Ltd.
- Entera Bio Ltd.
- Reliance Life Sciences
- Enteris BioPharma
- Luye Pharma
- Sandoz International GmbH
- Shanghai Henlius Biotech
- Haoma Medica
- Outlook Therapeutics
- SB 16
- Calcitonin oral
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/3i83zf